Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) from a neutral rating to an overweight rating in a report published on Monday, Marketbeat reports. They currently have $20.00 target price on the stock. FDMT has been the subject of a number of other research reports. B. Riley Financial reissued a “buy” […]

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) was upgraded by stock analysts at B. Riley Financial from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, Briefing.com reports. The brokerage currently has a $21.00 price target on the biotechnology company’s stock. B. Riley Financial’s target price […]

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) gapped up prior to trading on Monday after B Riley upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $8.37, but opened at $9.10. Capricor Therapeutics shares last traded at $8.8360, with a volume of 692,821 shares changing hands. […]